<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018365</url>
  </required_header>
  <id_info>
    <org_study_id>190012</org_study_id>
    <nct_id>NCT04018365</nct_id>
  </id_info>
  <brief_title>A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance</brief_title>
  <acronym>EMPIRE-01</acronym>
  <official_title>A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kobe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, single-arm study with regard to the efficacy and safety of&#xD;
      empagliflozin in patients with refractory diabetes mellitus with insulin resistance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the clinical efficacy of a treatment with empagliflozin in refractory diabetes&#xD;
      mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes&#xD;
      mellitus) by using the HbA1c change at Week 24 of treatment from baseline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change at Week 24 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change rate at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change rate at Week 24 of the treatment from baseline, change rates will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c change at Week 12 of the treatment from baseline</measure>
    <time_frame>at Week 12 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change at Week 12 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c over time</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The HbA1c level at measurement time point is tabulated by patient, as well as plotting the HbA1c level over time by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of HbA1c at each time point will be calculated and tabulated, as well as displaying the mean at each measurement time point with error bar of standard deviation by line graph.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG) over time</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The FPG level at measurement time point is tabulated by patient, as well as plotting the FPG level over time by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of FPG at each time point will be calculated and tabulated, as well as displaying the mean at each measurement time point with error bar of standard deviation by line graph.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG change at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the FPG change at Week 24 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin dose</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The insulin dose of each patient will be tabulated by time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose for 2 hours over time</measure>
    <time_frame>2 Weeks from Day0 and Day140</time_frame>
    <description>The postprandial glucose for 2 hours at measurement time point is tabulated by patient, and the glucose level over time is plotted by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of postprandial glucose for 2 hours at each time point will be tabulated, and the mean at each measurement time point with an error bar of standard deviation will be displayed by line graph.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Insulin Resistance - Type A</condition>
  <condition>Insulin Resistance - Type B</condition>
  <condition>Lipoatrophic Diabetes Mellitus</condition>
  <condition>Insulin Resistance Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of &lt;7.0%, 10 mg will be continued: in case of &gt;=7.0%, it will be increased to 25 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tablets</intervention_name>
    <description>The administration is oral administration with water before or after breakfast.</description>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <other_name>BI10773</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) A patient who has been diagnosed with insulin resistance syndrome (type A, type B,&#xD;
             type non-A non-B) or lipoatrophic diabetes mellitus prior to obtaining consent&#xD;
&#xD;
          -  2) A patient who has received consistent dosage and administration of drugs aiming a&#xD;
             hypoglycemic effect and consistent instructions of diet therapy/exercise therapy for&#xD;
             more than 12 weeks before enrollment&#xD;
&#xD;
          -  3) A patient with &gt;= 7.0 % of HbA1c at the time of screening&#xD;
&#xD;
          -  4) A patient, if taking other SGLT2 inhibitor than empagliflozin, whose SGLT2&#xD;
             inhibitor can be washed out for more than 12 weeks prior to starting empagliflozin&#xD;
&#xD;
          -  5) A patient at the age of &gt;=20 years at the time of consent&#xD;
&#xD;
          -  6) A patient who has received sufficient explanation with regard to information such&#xD;
             as the objectives and details of this study, expected drug efficacy/pharmacological&#xD;
             action, and risks, and has given written consent by her/himself.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) A patient with a medical history of acute coronary syndrome (including&#xD;
             non-ST-elevation myocardial infarction, ST-elevation myocardial infarction, and&#xD;
             unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months&#xD;
             before obtaining consent&#xD;
&#xD;
          -  2) A patient with suspected hepatic dysfunction, that either of serum ALT, AST or&#xD;
             alkaline phosphatase in the screening period is exceeding 3-fold of upper limit of&#xD;
             normal rang&#xD;
&#xD;
          -  3) A patient who is receiving a systemic steroid at the time of consent (except for&#xD;
             type B)&#xD;
&#xD;
          -  4) A patient whose thyroid hormone product dose has been changed within 6 weeks before&#xD;
             obtaining consent&#xD;
&#xD;
          -  5) A patient with unstable endocrine diseases other than diabetes mellitus&#xD;
&#xD;
          -  6) A patient with hemolysis or blood diseases that destabilize erythrocytic cells and&#xD;
             other various disorders (e.g., malaria, babesiosis, hemolytic anemia).&#xD;
&#xD;
          -  7) A premenopausal female patient (the latest menstruation was within 1 year before&#xD;
             obtaining consent), a lactating or pregnant patient, or a patient who may be pregnant&#xD;
             (without hysterectomy or ovariectomy) who has no intention to use efficacious&#xD;
             contraception defined in this study during the treatment period and would not agree to&#xD;
             receive regular pregnancy tests during the treatment period&#xD;
&#xD;
          -  8) A patient who has experienced alcohol abuse or drug abuse within 3 months before&#xD;
             obtaining consent, which may disturb the study participation&#xD;
&#xD;
          -  9) A patient who is in the condition that makes it difficult to administer the study&#xD;
             drug&#xD;
&#xD;
          -  10) A patient with renal dysfunction of eGFR (MDRD calculating formula) &lt; 45&#xD;
             mL/min/1.73 m2 in the screening period&#xD;
&#xD;
          -  11) A patient who indicates a hypersensitivity response to empagliflozin or its&#xD;
             excipients, or a patient with lactose-intolerance&#xD;
&#xD;
          -  12) A patient with severe ketosis, diabetic coma or precoma, severe infection,&#xD;
             perioperative status, or serious trauma&#xD;
&#xD;
          -  13) A patient that the investigator and/or subinvestigator, etc., has judged to be&#xD;
             ineligible to this study for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wataru Ogawa</last_name>
    <role>Study Chair</role>
    <affiliation>Kobe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIhon University Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe University</investigator_affiliation>
    <investigator_full_name>Wataru Ogawa</investigator_full_name>
    <investigator_title>Professor, Division of Diabetes and Endocrinology</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>refractory diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Lipoatrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

